The abstract is read at the publisher; the summary is JClub's.
L013, an NRF2 degrader, reduces NRF2 abundance and suppresses tumor growth in NRFA-subtype esophageal squamous cell carcinoma models, including patient-derived organoids and xenografts.
- Why it matters: NRFA-subtype ESCC is linked to poor prognosis and limited conventional therapy response, partly because excessive NRF2 protein accumulation supports oncogenic signaling.
- What they did: L013 was identified from high-content screening of 725 CRBN ligand-based degraders and shown to lower NRF2 abundance and NFE2L2 mRNA in ESCC cells via UPS-linked, Cullin-dependent E3 ligase activity plus scaffold-driven impairment of NFE2L2 transcriptional output.
- The result: In ESCC PDOs, LUSC PDOs, and ESCC xenografts, L013 decreases NRF2 levels and suppresses tumor growth without overt systemic toxicity under the tested dosing regimen.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.